Beyond Weight Loss: What GLP-1 Drugs May Be Doing to the Liver, the Brain's Reward System, and Older Patients

For a category of medication that started out treating type 2 diabetes, GLP-1s have had an unusually wide-ranging year. Researchers keep noticing effects that weren't the point of the prescription — changes in cravings, changes in the liver, changes in how older bodies respond. None of this means these drugs are miracle therapies. It does mean the story is bigger than 'they help people lose weight,' and worth understanding if you or someone you love is considering one.

The evidence base here is best described as moderate: real signals from real studies, but a mix of human cohort data and animal work, and not yet the kind of large randomized trials that settle a question for good.

One of the more striking findings of the past year comes from a 2025 review in Diabetes & Metabolism that compared two ways people pursue major weight loss: bariatric surgery and GLP-1 receptor agonists. The pattern that emerged was almost mirror-image. Across eleven observational cohorts — mostly studying gastric bypass — the prevalence of alcohol use disorder was roughly twice as high more than two years after surgery. Across five studies of GLP-1RA therapy, mostly semaglutide, the prevalence was roughly halved.

Similar directional findings showed up for food addiction, smoking, cannabis, cocaine, and opioid use. The authors propose a tidy if unproven explanation for the surgical pattern: 'addiction transfer,' where the brain, deprived of food as a coping tool, finds another. For the GLP-1 side, they point to effects on the dopamine reward pathway, central GABA release, and neuronal inflammation — biology that may dampen the pull of compulsive behaviors rather than redirect it.

A reasonable parent's response to all of this: interesting, not settled. These are observational data, vulnerable to the usual confounders (who chooses which therapy, who stays in care, who gets asked). They suggest a hypothesis worth testing, not a reason to pick a drug.

The second study is the one to read with the most caution — and the most curiosity. In a 2025 paper in International Immunopharmacology, researchers tested tirzepatide, the dual GIP/GLP-1 receptor agonist, in diabetic mice and found it reduced body weight, improved insulin resistance, lowered serum and hepatic lipid levels, and eased liver injury. Compared head-to-head with semaglutide, tirzepatide came out ahead at clearing fat from the liver.

The mechanism is where it gets genuinely interesting. The researchers traced the benefit into the gut: tirzepatide shifted the microbiota toward beneficial genera including Akkermansia, and rebalanced bile acid metabolism in a direction that downregulated intestinal FXR signaling — a pathway increasingly linked to how the liver handles fat.

The caveat is large and worth repeating. These were mice. Microbiome and bile-acid biology often look cleaner in rodents than they translate in humans, and hepatic steatosis in people is a more heterogeneous problem. The study is a strong mechanistic lead, not a clinical promise.

The third study — the SEMA-elderly real-world cohort, published in Diabetes, Obesity & Metabolism in 2025 — tackled a question clinicians actually face every week: does the oral form of semaglutide work, and is it tolerable, in patients aged 65 and older with type 2 diabetes?

In 101 patients with a mean age of 74.7, six months of daily oral semaglutide brought mean HbA1c down by 0.44%, with the share of patients hitting an HbA1c at or below 7% climbing from 36.6% at baseline to 61.7%. Mean body weight slipped from 76.8 kg to 73.7 kg. Waist circumference, total and LDL cholesterol, and systolic blood pressure all fell. Adverse events were reported in 10.9% of patients, and 6.9% discontinued treatment.

This is a small, single-arm, real-world study — not a randomized trial — and that limits how confidently anyone can generalize. But for a population that often gets excluded from drug development, it's a useful data point: oral semaglutide appeared to work, and most older patients in this cohort stayed on it.

If you're reading this between night feeds or in the five quiet minutes before the school pickup, here's the smallest useful version. The new GLP-1 research is genuinely promising in three directions at once: a possible dampening of addictive behaviors, possible benefits for the fatty liver that often travels with type 2 diabetes, and reasonable real-world performance in older adults. None of those findings are the kind of locked-in certainty that should drive a decision on its own.

If a GLP-1 is on the table for you or a family member — for diabetes, for weight, for a metabolic picture your clinician is worried about — these studies are worth bringing into that conversation. They are not a substitute for it. A clinician who knows the rest of the medical chart is the right person to weigh benefits, side effects, cost, and the very ordinary question of whether a daily or weekly medication fits your actual life.

The honest summary of this moment in metabolic medicine: the drugs are doing more than we first thought, and we still have more to learn. Both things can be true at the same time.